Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions

Sanofi60 enrolled

Overview

The rationale of the study is to clarify whether the supplementation of irbesartan with ciprofibrate could increase the antihypertensive effect, could improve the endothelial functions, and/or could affect the atherogenic small-dense LDL-, oxydized LDL concentrations, onto the paraoxinase activity and on the CRP and insulin levels.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hypertension Dyslipidemia

Interventions

IrbesartanDRUG

CiprofibrateDRUG

Eligibility

Sex: ALLMin age: 45 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * hypertensive + dyslipidemic + damaged endothelial function Exclusion Criteria: * hepatic and kidney damage, * IDDM (Insulin Dependent Diabetes Mellitus) * Freckson V type hyperlipoproteinaemia The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (1)

Sanofi-aventis

Budapest, Hungary

Outcomes

Primary Outcomes

Microvascular reactivity

Secondary Outcomes

Reach of target blood pressure

Measurements of safety laboratory parameters

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.